The obesity epidemic is bursting at the seams.  

According to the World Health Organization, obesity has tripled since 1975.  More than 1.9 billion adults were overweight, as of 2016, with more than 650 million considered obese. By 2030, about 20% of the global population will be obese, according to the National Centers for Biotechnology Information.  

That’s not good at all.

Worse, according to the World Obesity Federation, “In its World Obesity Atlas 2023, the federation said the economic impact of overweight and obesity on the world is set to reach $4.32tn—nearly 3% of global gross domestic product.”

Terrible, right?

But also profitable for investors. With new weight loss treatments –most of which require a quick jab—the market could be worth $100 billion by 2030, says Goldman Sachs.

And while Eli Lilly and Novo Nordisk already popped on the news, there are more.

Keep an eye on Structure Therapeutics (GPCR), for example.

According to JPMorgan, it’s an overlooked player in the weight loss treatment market. The firm has an overweight rating on the stock, with a price target of $65.

“We think the opportunity for oral GLP-1s is underappreciated and think this market could generate $30bn in sales by 2035,” added the firm, as quoted by CNBC. “GPCRs lead asset, 1290, is a pure-play option for this opportunity, and even a small share would support substantial upside to the stock.”